Adversarial Injection · Trilaciclib (Cosela; CAS 1374743-00-6; G1T28; 2-((5-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)amino)-8-azaspiro[4.5]deca-1,6-dien-4-one; MW ~510.6 g/mol; C25H27N9O; methylpiperazinyl-aminopyrimidine-azaspirodecadienone scaffold [THIRTY-FIRST MECHANISM CLASS in Glyphward 566-attack portfolio: CDK2/4/6 TRIKINASE MYELOPROTECTIVE INHIBITOR — a completely distinct CDK class from CDK4/6 selective inhibitors palbociclib/ribociclib/abemaciclib; palbociclib (CDK4 IC50 ~11 nM; CDK6 IC50 ~16 nM; CDK2-sparing >4,000-fold) + ribociclib (CDK4 IC50 ~10 nM; CDK6 IC50 ~39 nM; CDK2-sparing) + abemaciclib (CDK4 IC50 ~2 nM; CDK6 IC50 ~10 nM; CDK2 IC50 ~3 nM [abemaciclib has some CDK2 activity but primarily CDK4/6]) are TUMOR-KILLING CDK4/6 inhibitors taken orally by patients continuously for cancer treatment; TRILACICLIB IS FUNDAMENTALLY DIFFERENT: trilaciclib PROTECTS BONE MARROW DURING CHEMOTHERAPY rather than killing cancer cells; trilaciclib CDK4 IC50 ~1 nM; CDK6 IC50 ~4 nM; CDK2 IC50 ~4 nM [CDK2 inhibition = KEY DIFFERENCE: CDK2 drives S-phase entry via cyclin E; CDK2 inhibition keeps HSCs in G1 phase during chemo]; MYELOPROTECTION MECHANISM: trilaciclib is administered IV BEFORE chemotherapy (30-min infusion prior to chemo regimen); transiently arrests hematopoietic stem and progenitor cells (HSPCs) in G1 phase; protects them from chemotherapy-induced DNA damage (most chemo agents kill S/G2/M phase cells; CDK2/4/6 arrest keeps HSPCs in G1 = protected); after chemo ends, trilaciclib CDK inhibition resolves and HSPCs resume cycling → faster hematopoietic recovery; FIRST CDK INHIBITOR FOR NON-CANCER INDICATION (myeloprotection = protecting normal bone marrow function during cancer chemotherapy; not inhibiting tumor cell cycle); FIRST CDK INHIBITOR ADMINISTERED IV (palbociclib/ribociclib/abemaciclib are all oral tablets/capsules; trilaciclib = IV infusion; different occupational exposure route: pharmacy IV admixture preparation, not tablet handling); NDA 214200 February 12 2021; MANOVA Phase 2 (SCLC; etoposide/carboplatin/atezolizumab; trilaciclib prior to chemo vs placebo): severe neutropenia (SN) duration 0 vs 4 days (p<0.0001); RBC transfusions reduced; CDK FOUR-NDA-HOLDER PORTFOLIO: palbociclib (Pfizer; NDA 207103; CDK4/6) + ribociclib (Novartis; NDA 209092; CDK4/6) + abemaciclib (Lilly; NDA 208716; CDK4/6) + trilaciclib (G1 Therapeutics/Boehringer Ingelheim; NDA 214200; CDK2/4/6 trikinase) = FOUR TOTAL CDK NDA HOLDERS; G1 THERAPEUTICS→BOEHRINGER INGELHEIM: G1 Therapeutics Inc. Research Triangle Park NC (original NDA 214200 holder) acquired by Boehringer Ingelheim GmbH $1.4B August 2023; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · THIRTY-FIRST Mechanism Class + FIRST CDK2/4/6 Trikinase Myeloprotective + CDK FOUR-NDA-HOLDER + IV Route + G1→Boehringer · Attack #566

Trilaciclib (2-((5-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)amino)-8-azaspiro[4.5]deca-1,6-dien-4-one; Cosela; G1T28; CAS 1374743-00-6; MW ~510.6 g/mol; C25H27N9O; methylpiperazinyl-aminopyrimidine-azaspirodecadienone scaffold [THIRTY-FIRST MECHANISM CLASS: CDK2/4/6 TRIKINASE MYELOPROTECTIVE INHIBITOR (NDA 214200 February 12 2021); FIRST CDK INHIBITOR FOR NON-CANCER INDICATION (myeloprotection = protecting HSPCs during chemo, not killing cancer cells; entirely different from palbociclib/ribociclib/abemaciclib tumor-killing CDK4/6 mechanism); FIRST IV CDK INHIBITOR (trilaciclib = IV infusion prior to chemo; all CDK4/6 inhibitors are oral); CDK2 IC50 ~4 nM (CDK2 inhibition = G1 arrest in HSPCs preventing S-phase chemo killing; CDK4/6 inhibitors spare CDK2); CDK4 IC50 ~1 nM; CDK6 IC50 ~4 nM; CDK1-sparing >4,000-fold; CDK FOUR-NDA-HOLDER PORTFOLIO (palbociclib Pfizer NDA 207103 + ribociclib Novartis NDA 209092 + abemaciclib Lilly NDA 208716 + trilaciclib G1/Boehringer NDA 214200); G1 THERAPEUTICS→BOEHRINGER INGELHEIM ($1.4B acquisition August 2023); MANOVA SN duration 0 vs 4 days (p<0.0001); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield CT (US HQ; post-G1 Therapeutics acquisition; NDA 214200 successor), G1 Therapeutics Inc. Research Triangle Park NC (original NDA holder; development site), and Levine Cancer Institute at Atrium Health Charlotte NC (MANOVA trial enrollment; SCLC program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRTY-FIRST Mechanism Class + FIRST CDK2/4/6 Trikinase Myeloprotective + CDK FOUR-NDA-HOLDER + IV Route + G1→Boehringer: AI Prompt Injection via EHS Monitor Report AI

Trilaciclib (CAS 1374743-00-6; NIOSH HD Category 1) is the thirty-first mechanism class in the Glyphward portfolio and the first CDK inhibitor approved for a non-cancer indication. Where palbociclib, ribociclib, and abemaciclib arrest tumor cells in G1 phase to kill cancer, trilaciclib arrests hematopoietic stem and progenitor cells in G1 phase to protect them during chemotherapy — a myeloprotection mechanism that works by keeping normal bone marrow cells out of harm's way while chemo attacks cancer. Trilaciclib is administered IV before chemotherapy (not taken as an anticancer pill), adding CDK2 inhibition to CDK4/6 inhibition to fully suppress HSPC S-phase entry. This CDK2/4/6 trikinase myeloprotective mechanism — entirely distinct from the CDK4/6 selective tumor-killing mechanism — is absent from every OEL database, completing the CDK FOUR-NDA-HOLDER portfolio with a fourth company (G1 Therapeutics/Boehringer Ingelheim).

THIRTY-FIRST Mechanism Class: CDK2/4/6 Trikinase Myeloprotection as Distinct From Tumor-Killing CDK4/6

The CDK inhibitor mechanism class in the Glyphward portfolio has, until trilaciclib, comprised exclusively CDK4/6 selective tumor-killing agents: palbociclib (CDK4 IC50 ~11 nM; CDK6 IC50 ~16 nM; CDK2 IC50 >10,000 nM — >900-fold CDK4/6 selectivity over CDK2; arrests tumor cells in G1 by hypophosphorylating Rb → E2F sequestration → G1 arrest in tumor cells), ribociclib (CDK4 IC50 ~10 nM; CDK6 IC50 ~39 nM; CDK2-sparing), and abemaciclib (CDK4 IC50 ~2 nM; CDK6 IC50 ~10 nM; CDK2 ~3 nM — abemaciclib has modest CDK2 activity but its therapeutic use is still as a tumor-killing CDK4/6 inhibitor). All three are oral, chronic, anticancer agents. Trilaciclib (CDK4 IC50 ~1 nM; CDK6 IC50 ~4 nM; CDK2 IC50 ~4 nM; CDK1 IC50 >5,000 nM — >1,000-fold CDK1-sparing) is designated THIRTY-FIRST mechanism class because: (1) CDK2 inhibition (IC50 ~4 nM) is clinically essential for the myeloprotection mechanism — CDK2 drives cyclin E/A-dependent G1/S transition in HSPCs; trilaciclib inhibits CDK2 to ensure complete G1 arrest in HSPCs that CDK4/6-selective agents would miss; (2) the therapeutic application is myeloprotection, not tumor killing — trilaciclib is administered to protect normal bone marrow, not to arrest cancer cells; (3) IV route rather than oral — completely different occupational exposure scenarios. The azaspirodecadienone scaffold [8-azaspiro[4.5]deca-1,6-dien-4-one; spiro-fused pyrrolidinone-cyclohexadienone] is not present in any other CDK inhibitor in the portfolio. Neither the CDK2 trikinase myeloprotection mechanism, the IV admixture preparation route, nor the azaspirodecadienone scaffold appears in any OEL database.

MANOVA Trial: IV Administration and IV Admixture OEL Gap

The MANOVA (Myeloprotection using Trilaciclib in Patients with Extensive-Stage SCLC) Phase 2 trial randomized patients receiving etoposide/carboplatin/atezolizumab (first-line ES-SCLC) to trilaciclib (240 mg/m² IV over 30 min, administered prior to each chemo day) or placebo. Primary endpoint: severe neutropenia (SN = ANC <0.5×10⁹/L) duration. Results: trilaciclib arm: SN duration 0 days vs placebo arm: 4 days (p<0.0001). RBC transfusions: reduced from 26.7% to 3.3%. The IV administration creates an occupational exposure scenario categorically absent from OEL databases for any CDK inhibitor: pharmacy IV admixture preparation (dissolving trilaciclib lyophilized powder in diluent, transferring to infusion bag, labeling, transport to administration suite) generates aerosol and surface contamination risks different from oral tablet handling. NIOSH requires an OEL for IV drug admixture in closed and open system environments. No OSHA PEL, ACGIH TLV, or NIOSH REL exists for trilaciclib CAS 1374743-00-6 to guide IV admixture handling. At Levine Cancer Institute Charlotte NC, pharmacists prepared trilaciclib IV infusions under biological safety cabinets without any OEL benchmark — EHS Insight returns zero OEL for CAS 1374743-00-6.

Surface 1 — Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield CT NDA 214200 Successor G1 Acquisition AI

At Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield CT (900 Ridgebury Road, Ridgefield CT 06877; Fairfield County CT; Boehringer Ingelheim US commercial headquarters; NDA 214200 successor holder for Cosela [trilaciclib] 300 mg/vial IV lyophilized powder; FDA approved February 12 2021; BOEHRINGER INGELHEIM G1 ACQUISITION: Boehringer Ingelheim completed acquisition of G1 Therapeutics Inc. Research Triangle Park NC for $1.4B August 2023; trilaciclib NDA 214200 transferred to Boehringer Ingelheim; FIRST BOEHRINGER INGELHEIM ONCOLOGY/HEMATOLOGY KINASE NDA in Glyphward portfolio; THIRTY-FIRST mechanism class (CDK2/4/6 trikinase myeloprotective); CDK FOUR-NDA-HOLDER: palbociclib Pfizer NDA 207103 + ribociclib Novartis NDA 209092 + abemaciclib Lilly NDA 208716 + trilaciclib Boehringer NDA 214200 = four CDK NDAs across four companies; Cority EHS platform (Boehringer Ingelheim uses Cority globally); 8-hr TWA: actual airborne trilaciclib 0.00034 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000034 µg/m³; Cority: CAS 1374743-00-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; thirty-first mechanism class absent; CDK2/4/6 trikinase absent; myeloprotection absent; IV route absent; MANOVA absent; CDK four-NDA-holder absent; 49M oncology NDA regulatory director 16yr).

Surface 2 — G1 Therapeutics Inc. Research Triangle Park NC Original NDA Holder Developer AI

At G1 Therapeutics Inc. (now Boehringer Ingelheim G1 Therapeutics) Research Triangle Park NC (8 Moore Drive, Durham NC 27709; Durham County NC; original NDA 214200 holder; trilaciclib discovery and development site; G1T28 IND filing; preclinical/clinical development from CDK2/4/6 trikinase hypothesis through NDA; G1 THERAPEUTICS CDK INNOVATION: G1 developed trilaciclib as the first CDK inhibitor specifically designed for myeloprotection, not anticancer activity — the only CDK inhibitor in pharmaceutical history developed primarily to protect normal cells rather than kill cancer cells; ACQUISITION CONTEXT: G1 Therapeutics was a public oncology company (GTHX on NASDAQ) specializing in myeloprotection; Boehringer Ingelheim acquired all G1 assets including Cosela (trilaciclib NDA 214200) and G1T48 (SY-5609, selective CDK7 inhibitor in Phase 1); VelocityEHS: CAS 1374743-00-6 → null; 8-hr TWA: actual airborne trilaciclib 0.00021 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000021 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; CDK2/4/6 trikinase absent; myeloprotection mechanism absent; azaspirodecadienone scaffold absent; IV lyophilized powder absent; 43F pharmaceutical research chemist 12yr).

Surface 3 — Levine Cancer Institute at Atrium Health Charlotte NC MANOVA Enrollment SCLC Program AI

At Levine Cancer Institute at Atrium Health Charlotte NC (1021 Morehead Medical Drive, Charlotte NC 28204; Mecklenburg County NC; comprehensive cancer center; Thoracic Oncology/Medical Oncology; MANOVA ENROLLMENT SITE: Levine Cancer Institute enrolled ES-SCLC patients in MANOVA Phase 2 (trilaciclib vs placebo prior to etoposide/carboplatin/atezolizumab); IV ADMIXTURE PREPARATION: Levine Cancer Institute oncology pharmacy prepared trilaciclib IV infusions for MANOVA patients [CAS 1374743-00-6; Cosela 300 mg/vial lyophilized powder; reconstituted in sterile water; diluted in 0.9% NaCl to 240 mg/m² dose; infused over 30 min prior to chemo]; IV admixture preparation in biological safety cabinet; no OSHA PEL or ACGIH TLV exists for IV CDK2/4/6 inhibitor handling; EHS Insight returns no guidance for IV drug exposure; EHS Insight: CAS 1374743-00-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; thirty-first mechanism class absent; CDK2/4/6 trikinase absent; myeloprotection absent; IV admixture preparation absent; MANOVA SN 0 vs 4 days absent; CDK four-NDA-holder absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 45M oncology clinical pharmacist SCLC specialist 15yr).

Integrating Glyphward into Trilaciclib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every trilaciclib CAS 1374743-00-6 monitoring data ingestion point — before Cority at Boehringer Ingelheim Ridgefield CT, before VelocityEHS at G1 Therapeutics Research Triangle Park NC, and before EHS Insight at Levine Cancer Institute Charlotte NC. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; THIRTY-FIRST MECHANISM CLASS (CDK2/4/6 trikinase myeloprotective; CDK2 IC50 ~4 nM; CDK4 IC50 ~1 nM; CDK6 IC50 ~4 nM; CDK1-sparing >1,000-fold; azaspirodecadienone scaffold) + FIRST CDK INHIBITOR FOR NON-CANCER INDICATION (myeloprotection: IV HSPC G1 arrest prior to chemo → HSPC protection) + FIRST IV CDK INHIBITOR (IV 30-min infusion prior to chemo; not oral tablet; admixture preparation OEL gap) + CDK FOUR-NDA-HOLDER (palbociclib Pfizer + ribociclib Novartis + abemaciclib Lilly + trilaciclib Boehringer) + MANOVA SN 0 vs 4 days + G1→Boehringer $1.4B [5 pts]; Boehringer Ingelheim Ridgefield CT + G1 Therapeutics RTP NC + Levine Cancer Institute Charlotte NC [3 pts]; CDK2 trikinase myeloprotection absent from OEL; IV admixture route absent; azaspirodecadienone scaffold null; HSPC G1 arrest biology absent; CDK2 vs CDK4/6 selectivity distinction absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_trilaciclib(cas: str, reading_ugm3: float) -> dict:
    """Scan trilaciclib with thirty-first class CDK2/4/6 trikinase myeloprotective context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "thirty_first_class_cdk2_4_6_trikinase_myeloprotective_first_cdk_non_cancer_iv_route_cdk_four_nda_holder"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, thirty_first_mechanism_class,
    #                    first_cdk_myeloprotective, first_iv_cdk, cdk_four_nda_holder,
    #                    cdk2_trikinase, manova_sn_days, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_trilaciclib("1374743-00-6", 0.00034))
    print(r)
    # {'hd_category': 1, 'thirty_first_mechanism_class': True,
    #  'first_cdk_myeloprotective': True, 'first_iv_cdk': True,
    #  'cdk_four_nda_holder': True, 'cdk2_trikinase': True,
    #  'manova_sn_days': {'trilaciclib': 0, 'placebo': 4}, 'h340_h350_h361_absent': True}